drugset / Trial / NCT02025621

Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

NCT02025621

Phase 3 Completed 882 enrolled Tenax Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

A study to evaluate levosimendan compared with placebo in reducing the composite event rate of all-cause death, perioperative MI, need for new dialysis, or use of mechanical assist (IABP, LVAD or ECMO) in subjects with reduced ejection fraction undergoing cardiac surgery on cardiopulmonary bypass (CPB).

Timeline

Start
2014-07
Primary completion
2016-11
Completion
2016-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Levosimendan Other / unclassified 0.1 ug/kg Intravenous